Nouvelle déclaration d'incident
No de la demande: 2021-0399
Numéro de référence du titulaire d'homologation: 2020-US-043261
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: NEW JERSEY
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 2596-139
Nom du produit: Hartz UltraGuard Pro Flea and Tick Collar (non-specific)
Autre (préciser)
CollarOui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Femme
0.58
7
lbs
Cutanée
>3 days <=1 wk / >3 jours <=1 sem
>3 days <=1 wk / >3 jours <=1 sem
Système
Persisted until death
Non
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 10-Nov-2020, a 7 month old, 7 pound, intact, female, Domestic Shorthair cat, in unknown condition, with concomitant medical condition of fleas, was administered 1 collar of Hartz UltraGuard Pro Flea and Tick Collar (non-specific) (Tetrachlorvinphos (Rabon) / S Methoprene) via the topical route by the animal owner. The animal owner suspected the cat may have been pregnant at the time of product application. On 17-Nov-2020, the cat developed ataxia, seizures, and then died. The cat was not evaluated by a veterinarian and no treatments were performed. It is unknown if a necropsy was performed. No further information was received in this case.
Mort
Assessment: This product has a wide margin of safety in cats following labeled use. If some product residue was ingested, mild GI upset may occur. The onset of signs 1 week post-application is unusual and severe signs progressing to death do not fit the toxicological profile of the product. Other causes including unknown trauma, toxin exposure, congenital conditions, infectious diseases, and severe flea anemia should be considered following sudden death in a young cat. Without diagnostics, this case cannot be evaluated further. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.